Mammakarzinom beim Mann

Das Mammakarzinom des Mannes ist für viele Behandler und Laien ein unbekanntes Feld. Der Patient wird oft bei unterschiedlichen Ärzten vorstellig, bevor die richtige Diagnose gestellt wird – dann häufig zu spät. Der folgende Artikel soll diese Erkrankung in den Fokus rücken und Risikofaktoren, Einleitung der Diagnostik und Therapie aufzeigen. Im beginnenden Zeitalter der molekularen Medizin soll zudem ein Blick auf die Genetik geworfen werden.

Schlüsselwörter

Mammakarzinom - Mann - Brustkrebs beim Mann - Diagnostik - Genetik

• Literatur

• 1 Zentrum für Krebsregisterdaten (RKI), Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.. Krebs in Deutschland für 2015/2016. 12. Ausg. korrigierte Fassung vom 17.08.2020. Robert Koch-Institut: Berlin; 2019
• 2 Wang F, Shu X, Meszoely I. et al. Overall Mortality After Diagnosis of Breast Cancer in Men vs. Women. JAMA Oncol 2019; 5: 1589-1596
• 3 Ernstmann N, Midding E, Halbach S. et al. Brustkrebs beim Mann – die Sicht der beteiligten Berufsgruppen auf die multiprofessionelle Versorgung einer seltenen Erkrankung. Gesundheitswesen 2020; 82: 614-619
• 4 Thomas DB, Jimenez M, McTieman A. et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol 1992; 135: 734-748
• 5 Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelterʼs syndrome. J Med Genet 1971; 8: 460
• 6 Hultborn R, Hanson C, Köpf I. et al. Prevalence of Klinefelterʼs syndrome in male breast cancer patients. Anticancer Res 1997; 17: 4293-4297
• 7 Brinton LA, Cook MB, McCormack V. et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst 2014; 106: djt465
• 8 Ferzoco RM, Ruddy KJ. The Epidemiology of Male Breast Cancer. Curr Oncol Rep 2015; 18: 1
• 9 Brinton LA, Key TJ, Kolonel LN. et al. Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. J Clin Oncol 2015; 33: 2041-2050
• 10 Olsson H, Bladstrom A, Alm P. Male gynecomastia and risk for malignant tumours–a cohort study. BMC cancer 2002; 2: 26
• 11 Johansen Taber KA, Morisy LR, Osbahr 3rd AJ. et al. Male breast cancer: risk factors, diagnosis, and management (Review). Oncol Rep 2010; 24: 1115-1120
• 12 Hsing AW, McLaughlin JK. Cocco Pet al. Risk factors for male breast cancer (United States). Cancer Causes Control 1998; 9: 269-275
• 13 Cook MB, Guénel P, Gapstur SM. et al. Tobacco and alcohol in relation to male breast cancer: an analysis of the male breast cancer pooling project consortium. Cancer Epidemiol Biomarkers Prev 2015; 24: 520-531
• 14 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, AWMF): Konsultationsfassung der S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms 2020. Version 4.04. AWMF-Registernummer: 032-045OL.
• 15 Scarpitta R, Zanna I, Aretini P. et al. Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing. Breast Cancer Res Treat 2019; 178: 557-564
• 16 Tai YC, Domchek S, Parmigiani G. et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 1811-1814
• 17 Nyberg T, Frost D, Barrowdale D. et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol 2020; 77: 24-35
• 18 Risch HA, McLaughlin JR, Cole DEC. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-1706
• 19 Mersch J, Jackson MA, Park M. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015; 121: 269-275
• 20 Oh M, McBride A, Yun S. et al. BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. J Natl Cancer Inst 2018; 110: 1178-1189
• 21 Evans DG, Susnerwala I, Dawson J. et al. Risk of breast cancer in male BRCA2 carriers. J Med Genet 2010; 47: 710-711
• 22 Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22: 735-742
• 23 Ibrahim M, Yadav S, Ogunleye F. et al. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer 2018; 18: 179
• 24 Castro E, Goh C, Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-1757
• 25 Patel VL, Busch EL, Friebel TM. et al. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res 2020; 80: 624-638
• 26 van Asperen CJ, Brohet RM, Meijers-Heijboer EJ. et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-719
• 27 Wasielewski M, den Bakker MA, van den Ouweland A. et al. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009; 116: 397-400
• 28 Meijers-Heijboer H, van den Ouweland A, Klijn J. et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59
• 29 Neuhausen S, Dunning A, Steele L. et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 2004; 108: 477-478
• 30 Liang M, Zhang Y, Sun C. et al. Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis. Mol Diagn Ther 2018; 22: 397-407
• 31 Fackenthal JD, Marsh DJ, Richardson AL. et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001; 38: 159-164
• 32 Marino MA, Gucalp A, Leithner D. et al. Mammographic screening in male patients at high risk for breast cancer: is it worth it?. Breast Cancer Res Treat 2019; 177: 705-711
• 33 Doyle S, Steel J, Porter G. Imaging male breast cancer. Clin Radiol 2011; 66: 1079-1085
• 34 Gao Y, Heller SL, Moy L. Male Breast Cancer in the Age of Genetic Testing: An Opportunity for Early Detection, Tailored Therapy, and Surveillance. Radiographics 2018; 38: 1289-1311
• 35 DʼOrsi CJ, Sickles EA, Mendelson EB. et al. ACR BI-RADS^® Atlas – Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013
• 36 Cardoso F, Bartlett JMS, Slaets L. et al. Characterization of male breast cancer: results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 2018; 29: 405-417
• 37 Leon-Ferre RA, Giridhar KV, Hieken TJ. et al. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 2018; 37: 599-614
• 38 Sánchez-Muñoz A, Vicioso L, Santonja A. et al. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. Mod Pathol 2018; 31: 299-306
• 39 Santonja A, Sanchez-Muñoz A, Fernández YP. et al. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes. J Clin Oncol 2016; 34: 1585-1585
• 40 Massarweh SA, Sledge GW, Miller DP. et al. Molecular Characterization and Mortality From Breast Cancer in Men. J Clin Oncol 2018; 36: 1396-1404